Habla un autor

Presentación del libro En el camino hacia la nación. Nacionalismo en el proceso de formación del estado y de la nación de la Nueva Granada, 1760- 1856. publicado por el Banco de la República en abril de 1994, a cargo del autor el profesor Hans Joachim Konig, el 5 de abril de ese mismo año, en la sala de conferencias de la Biblioteca Luis Ángel Arango

On the way to the "best childrens´s university": The supply and demand relationship under the principle of partcipation. Opportunities and challenges raised by the children´s university

I know the children’s university is the best university in the world,” says Elisabeth, who is 9 years old and an attendee at the children’s university in Vienna. This charming compliment paid to the children’s university organizers raises an opportunity for further critical inquiries. The statement puts “real” universities on a par with children’s universities and therefore contains the implicit question of the status of children’s universities in the educational landscape: as a hybrid of formal and non-formal education. The specialist conference “On the way to the ‘best Children’s University’: The Supply and Demand Relationship under the Principle of Participation. Opportunities and Challenges”, took place from 8 to 10 May at the University of Cologne, addressed this intermediate position in all its facets. Further topics were possibilities for getting children involved as equal partners, and an international comparison of children’s university models. The conference was funded by the Ford Foundation and supported by KölnAlumni – Freunde und Förderer der Universität e.V. It was organized in partnership with the international children’s university network EUCUNET along with the multinational EU project “SiSCatalyst. Children as change agents for science and society”

Molecular matched targeted therapies for primary brain tumors—a single center retrospective analysis

PURPOSE: Molecular diagnostics including next generation gene sequencing are increasingly used to determine options for individualized therapies in brain tumor patients. We aimed to evaluate the decision-making process of molecular targeted therapies and analyze data on tolerability as well as signals for efficacy. METHODS: Via retrospective analysis, we identified primary brain tumor patients who were treated off-label with a targeted therapy at the University Hospital Frankfurt, Goethe University. We analyzed which types of molecular alterations were utilized to guide molecular off-label therapies and the diagnostic procedures for their assessment during the period from 2008 to 2021. Data on tolerability and outcomes were collected. RESULTS: 413 off-label therapies were identified with an increasing annual number for the interval after 2016. 37 interventions (9%) were targeted therapies based on molecular markers. Glioma and meningioma were the most frequent entities treated with molecular matched targeted therapies. Rare entities comprised e.g. medulloblastoma and papillary craniopharyngeoma. Molecular targeted approaches included checkpoint inhibitors, inhibitors of mTOR, FGFR, ALK, MET, ROS1, PIK3CA, CDK4/6, BRAF/MEK and PARP. Responses in the first follow-up MRI were partial response (13.5%), stable disease (29.7%) and progressive disease (46.0%). There were no new safety signals. Adverse events with fatal outcome (CTCAE grade 5) were not observed. Only, two patients discontinued treatment due to side effects. Median progression-free and overall survival were 9.1/18 months in patients with at least stable disease, and 1.8/3.6 months in those with progressive disease at the first follow-up MRI. CONCLUSION: A broad range of actionable alterations was targeted with available molecular therapeutics. However, efficacy was largely observed in entities with paradigmatic oncogenic drivers, in particular with BRAF mutations. Further research on biomarker-informed molecular matched therapies is urgently necessary. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-022-04049-w